RHRui Huang

Rui Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rui Huang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Churong Li

    Department of Radiation Oncology Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China Chengdu China

    1 shared publication
  • Dingqiang Yang

    Department of Oncology Xinqiao Hospital, Army Medical University Chongqing China

    1 shared publication
  • Fan Fei

    School of Medicine, Guizhou University, Guiyang, China

    1 shared publication
  • Fan Yang

    Department of Oncology Xinqiao Hospital, Army Medical University Chongqing China

    1 shared publication
  • Guanghui Li

    Department of Oncology Xinqiao Hospital, Army Medical University Chongqing China

    1 shared publication
  • Hang Liu

    School of Medicine, Guizhou University, Guiyang, China

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and safety of PLDR‐IMRT for the re‐irradiation of recurrent NPC: A prospective, single‐arm, multicenter trial

    by Rui Huang, Zhihui Li, Fan Yang, Yu Zhang, Yanhui Jiang, Churong Li, Hui Gao, Guanghui Li, Yimin Liu, Wenyan Guo, et al.

    Salvage treatment of locoregionally recurrent nasopharyngeal carcinoma (NPC) requires weighing the benefits of re-irradiation against increased risks of toxicity. Here, we evaluated the outcomes of patients treated with intensity-modulated-based pulsed low-dose-rate radiotherapy (PLDR-IMRT) to enhance the curative effect of salvage treatment and reduce RT-related SAEs. A prospective clinical trial was conducted from March 2018 to March 2020 at multiple institutions. NPC patients who experienced relapse after radical therapy were re-irradiated with a median dose of 60 Gy (50.4-70 Gy)/30 f (28-35 f) using PLDR-IMRT. Thirty-six NPC patients who underwent PLDR-IMRT for locoregional recurrence were identified. With a median follow-up of 26.2 months, the objective response rate (ORR) of the entire cohort was 91.6%. The estimated mPFS duration was 28 months (95% CI: 24.9-31.1), and the estimated mLRFS duration was 30.4 months (95% CI: 25.2-35.5). The overall survival (OS) rate for all patients was 80.6%, the progression-free survival (PFS) rate was 75% and the cancer-specific survival (CSS) rate was 88.9% at 1 year. The LRFS and DMFS rates were 88.9% and 91.7%, respectively, at 1 year. A combination of systematic therapies could provide survival benefits to patients who experience NPC relapse (p < 0.05), and a Karnofsky performance status (KPS) score of >= 90 was a favorable factor for local control (p < 0.05). The incidence of acute SAEs (grade 3+) from PLDR was 22.2%, and the incidence of chronic SAEs was 19.4% among all patients. PLDR-IMRT combined with systematic therapy can effectively treat patients with locoregionally recurrent nasopharyngeal carcinoma and causes fewer adverse events than the rates expected with IMRT.


  • Open Access

    The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

    by Yuanling Zhang, Junhao Chen, Hang Liu, Rui Mi, Rui Huang, Xian Li, Fei Fan, Xueqing Xie, Jie Ding

    Epigenetic modifications may alter the proliferation and differentiation of normal cells, leading to malignant transformation. They can also affect normal stimulation, activation, and abnormal function of immune cells in the tissue microenvironment. Histone methylation, coordinated by histone methylase and histone demethylase to stabilize transcription levels in the promoter area, is one of the most common types of epigenetic alteration, which gained increasing interest. It can modify gene transcription through chromatin structure and affect cell fate, at the transcriptome or protein level. According to recent research, histone methylation modification can regulate tumor and immune cells affecting anti-tumor immune response. Consequently, it is critical to have a thorough grasp of the role of methylation function in cancer treatment. In this review, we discussed recent data on the mechanisms of histone methylation on factors associated with immune resistance of tumor cells and regulation of immune cell function.